Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration

—  Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) (“Mydecine” or the “Company”), is pleased to announce that its subsidiary Mindleap Health’s (“Mindleap” ) telehealth platform will be officially available for download from the iOS and Android stores on September 30, 2020. Mindleap was founded with the goal of enhancing the wellbeing of millions of peopleContinue reading “Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration”

Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets

 — Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value. Topics that the special committee will discuss include, but limited to, a potential spin out of certain company assets. Currently, the company owns andContinue reading “Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets”

Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans

—  Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce that, further to its press release on June 10, 2020, it has entered into a definitive share exchange agreement (the “Share Exchange Agreement”) for the acquisition (the ” Acquisition “) of 100% of NeuroPharm Inc. (“NeuroPharm”), a Canadian-based developerContinue reading “Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans”

Mydecine Innovations Group Adds World Renowned, 7-Time Nobel Peace Prize Nominee Dr. M.S Reddy to its Scientific Advisory Board

— Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”), announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor. Dr. Reddy is one of the world’s most pre-eminent authorities in applied microbiology as it relates to dairy foods, probiotics,Continue reading “Mydecine Innovations Group Adds World Renowned, 7-Time Nobel Peace Prize Nominee Dr. M.S Reddy to its Scientific Advisory Board”

Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board

— Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board. Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and research institutions for the last 30 years. He holdsContinue reading “Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board”

Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

— Mydecine Innovations Group Inc. (CSE:MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”) is pleased to announce the addition of two key strategic advisors to the company’s Scientific Advisory Committee. The new members of the science team will provide scientific expertise and corporate strategy support as Mydecine begins its R&D program at its Innovation CenterContinue reading “Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist”

Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth Platform

 — Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) (“Mydecine” or the “Company”)is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. (“Mindleap”) for the acquisition of a 100% interest in MindLeap’s Digital Telehealth Platform focused on the emerging psychedelics industry. Pursuant to the share exchange agreement,Continue reading “Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth Platform”

Mydecine Innovations Group to Acquire NeuroPharm Inc.

Strategically Positioned on Therapies for Military, Veterans, Front-Line Personnel Globally to cope with Mental Health & Well-Being June 10, 2020 /PRNewswire/ — Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce it has signed a non-binding Letter of Intent (“LOI”) dated June 9, 2020 to acquire NeuroPharm Inc., (“NeuroPharm”) aContinue reading “Mydecine Innovations Group to Acquire NeuroPharm Inc.”

Newleaf Brands Announces its Move into State-of-the-art 7,500 sq. ft. Specialty Mycology R&D and Product Development Lab in Denver, Colorado

VANCOUVER, British Columbia, June 2, 2020 /CNW/ —  NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) (FSE: 0NF) (“NewLeaf Brands” or the “Company“), soon to put into effect its name change to Mydecine Group, is pleased to announce the completion of its wholly-owned and operated world class R&D Lab and Facilities focused on the mycology of the  fungtional© mushroom space. Earlier lastContinue reading “Newleaf Brands Announces its Move into State-of-the-art 7,500 sq. ft. Specialty Mycology R&D and Product Development Lab in Denver, Colorado”